Q3 EPS Forecast for Rocket Pharmaceuticals Lifted by Analyst

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Investment analysts at Wedbush upped their Q3 2025 earnings per share estimates for shares of Rocket Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 27th. Wedbush analyst Y. Zhong now expects that the biotechnology company will post earnings of ($0.46) per share for the quarter, up from their prior forecast of ($0.54). Wedbush currently has a "Outperform" rating and a $32.00 price target on the stock. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share. Wedbush also issued estimates for Rocket Pharmaceuticals' Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($2.04) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.52) EPS, FY2028 earnings at ($1.46) EPS and FY2029 earnings at ($1.20) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.02. During the same period last year, the firm posted ($0.66) EPS.

RCKT has been the subject of a number of other research reports. Morgan Stanley reaffirmed an "equal weight" rating and issued a $7.00 price target on shares of Rocket Pharmaceuticals in a research report on Wednesday. BMO Capital Markets reduced their price target on Rocket Pharmaceuticals from $30.00 to $8.00 and set an "outperform" rating for the company in a research report on Wednesday. Canaccord Genuity Group reduced their price target on Rocket Pharmaceuticals from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Scotiabank reduced their price target on Rocket Pharmaceuticals from $51.00 to $19.00 and set a "sector outperform" rating for the company in a research report on Wednesday. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Rocket Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $21.21.

Rocket Pharmaceuticals Stock Down 5.3%

Shares of NASDAQ:RCKT traded down $0.14 on Friday, reaching $2.48. The company had a trading volume of 7,402,317 shares, compared to its average volume of 1,878,766. Rocket Pharmaceuticals has a twelve month low of $2.19 and a twelve month high of $26.98. The stock has a 50-day moving average price of $6.20 and a 200 day moving average price of $9.45. The stock has a market capitalization of $264.83 million, a P/E ratio of -0.90 and a beta of 1.02. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06.

Insider Activity at Rocket Pharmaceuticals

In related news, insider Kinnari Patel acquired 21,099 shares of the firm's stock in a transaction on Wednesday, April 9th. The shares were bought at an average cost of $4.70 per share, with a total value of $99,165.30. Following the completion of the acquisition, the insider now owns 26,774 shares of the company's stock, valued at $125,837.80. This trade represents a 371.79% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Aaron Ondrey sold 7,489 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.29, for a total value of $39,616.81. Following the sale, the chief financial officer now directly owns 129,650 shares in the company, valued at $685,848.50. The trade was a 5.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 24.76% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of Rocket Pharmaceuticals by 796.2% in the 4th quarter. SG Americas Securities LLC now owns 54,921 shares of the biotechnology company's stock valued at $690,000 after purchasing an additional 48,793 shares during the period. KBC Group NV lifted its stake in shares of Rocket Pharmaceuticals by 159.6% in the 4th quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 3,366 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Rocket Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,329 shares of the biotechnology company's stock valued at $243,000 after purchasing an additional 1,824 shares during the period. Jennison Associates LLC lifted its stake in shares of Rocket Pharmaceuticals by 72.6% in the 4th quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company's stock valued at $884,000 after purchasing an additional 29,564 shares during the period. Finally, Strategic Financial Concepts LLC acquired a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at $141,000. Institutional investors and hedge funds own 98.39% of the company's stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.